Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | DDO | Q99489 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26565516 | 0.84 | LMNA (0.43) | LMNAHTTKDM4EPKMALDH1A1 | |
| SCHEMBL29615664 | 0.82 | POLB (0.48) | LMNAHTTKDM4EPKMALDH1A1 | |
| SCHEMBL3244018 | 0.82 | LMNA (0.54) | LMNAHTTKDM4EPKMALDH1A1 | |
| SCHEMBL8210689 | 0.77 | POLB (0.44) | LMNAHTTKDM4EPKMALDH1A1 | |
| SCHEMBL9716925 | 0.77 | LMNA (0.50) | LMNAHTTKDM4EPKMALDH1A1 | |
| SCHEMBL27705068 | 0.77 | LMNA (0.50) | LMNAHTTKDM4EPKMALDH1A1 | |
| SCHEMBL3668045 | 0.75 | HTT (0.48) | LMNAHTTKDM4EPKMALDH1A1 | |
| SCHEMBL29344184 | 0.74 | LMNA (0.39) | LMNAHTTKDM4EPKMALDH1A1 | |
| SCHEMBL1101881 | 0.74 | LMNA (0.52) | LMNAHTTKDM4EPKMALDH1A1 | |
| SCHEMBL6115897 | 0.73 | ALDH1A1 (0.62) | LMNAHTTKDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3018116-B1 | VITAMIN K2 INTERMEDIATES | KAPPA BIOSCIENCE AS (NO) | 2020-10-28 | — | — | EP | disclosed |
| US-20170283354-A1 | PROCESS FOR THE PREPARATION OF VITAMIN K2 | KAPPA BIOSCIENCE AS (NO) | 2017-10-05 | — | — | US | disclosed |
| US-20170283354-A1 | PROCESS FOR THE PREPARATION OF VITAMIN K2 | KAPPA BIOSCIENCE AS (NO) | 2017-10-05 | — | — | US | disclosed |
| EP-3018116-A1 | VITAMIN K2 INTERMEDIATES | Kappa Bioscience As (NO) | 2016-05-11 | — | — | EP | disclosed |
| US-20150210620-A1 | PROCESS FOR THE PREPARATION OF VITAMIN K2 | KAPPA BIOSCIENCE AS (NO) | 2015-07-30 | — | — | US | disclosed |
| US-20150210620-A1 | PROCESS FOR THE PREPARATION OF VITAMIN K2 | KAPPA BIOSCIENCE AS (NO) | 2015-07-30 | — | — | US | disclosed |
| US-9012693-B2 | Process for the preparation of vitamin K2 | KAPPA BIOSCIENCE AS (NO) | 2015-04-21 | — | — | US | disclosed |
| US-9012693-B2 | Process for the preparation of vitamin K2 | KAPPA BIOSCIENCE AS (NO) | 2015-04-21 | — | — | US | disclosed |
| US-20110207967-A1 | PROCESS FOR THE PREPARATION OF VITAMIN K2 | KAPPA BIOSCIENCE AS (NO) | 2011-08-25 | — | — | US | disclosed |
| US-20110207967-A1 | PROCESS FOR THE PREPARATION OF VITAMIN K2 | KAPPA BIOSCIENCE AS (NO) | 2011-08-25 | — | — | US | disclosed |
| WO-2010034999-A1 | CRYSTALLINE MENOQUINONE-7 (VITAMIN K2) | KAPPA BIOSCIENCE AS (NO) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283354-A1 | PROCESS FOR THE PREPARATION OF VITAMIN K2 | PROC, VKORC1, VKORC1L1 | LMNA 298/4885HTT 3689/4885KDM4E 249/4885 |
| US-20110207967-A1 | PROCESS FOR THE PREPARATION OF VITAMIN K2 | PROC, VKORC1, VKORC1L1 | LMNA 244/4885HTT 3814/4885KDM4E 264/4885 |
| US-20150210620-A1 | PROCESS FOR THE PREPARATION OF VITAMIN K2 | PROC, VKORC1, VKORC1L1 | LMNA 298/4885HTT 3689/4885KDM4E 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.